Hippocampal neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study

Husarova, Veronika; Bittšanský, Michal; Ondrejka, Igor; Kerna, V.; Dobrota, Dušan

doi:10.1016/j.pscychresns.2011.07.006

Cited by 20 publications

(9 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced levels of myo-inositol, a putative glial marker (Hattingen et al, 2008), are indicated in the cerebral spinal fluid (CSF) and in the frontal cortex in post-mortem data of individuals with affective disorders (Barkai, 1978, Shimon et al, 1997). Further, several independent proton magnetic resonance spectroscopy ( 1 H-MRS) studies report reduced resonance of myo-inositol in the prefrontal cortex (PFC) (Coupland et al, 2005), the ACC (Chen et al, 2014, Chiappelli et al, 2015, Frey et al, 1998) and hippocampus (Husarova et al, 2012) of depressed patients.…”

Section: Introductionmentioning

confidence: 99%

Variations in myo-inositol in fronto-limbic regions and clinical response to electroconvulsive therapy in major depression

Njau

Joshi

Leaver

et al. 2016

Journal of Psychiatric Research

View full text Add to dashboard Cite

Though electroconvulsive therapy (ECT) is an established treatment for severe depression, the neurobiological factors accounting for the clinical effects of ECT are largely unknown. Myo-inositol, a neurometabolite linked with glial activity, is reported as reduced in fronto-limbic regions in patients with depression. Whether changes in myo-inositol relate to the antidepressant effects of ECT is unknown. Using magnetic resonance spectroscopy (1H-MRS), we measured dorsomedial anterior cingulate cortex (dmACC) and left and right hippocampal myo-inositol in 50 ECT patients (mean age: 43.78, 14 SD) and 33 controls (mean age: 39.33, 12 SD) to determine cross sectional effects of diagnosis and longitudinal effects of ECT. Patients were scanned prior to treatment, after the second ECT and at completion of the ECT index series. Controls were scanned twice at intervals corresponding to patients’ baseline and end of treatment scans. Myo-inositol increased over the course of ECT in the dmACC (p = 0.042). A significant hemisphere by clinical response effect was observed for the hippocampus (p=0.003) where decreased myo-inositol related to symptom improvement in the left hippocampus. Cross-sectional differences between patients and controls at baseline were not detected. Changes in myo-inositol observed in the dmACC in association with ECT and in the hippocampus in association with ECT-related clinical response suggest the mechanisms of ECT could include gliogenesis or a reversal of gliosis that differentially affect dorsal and ventral limbic regions. Change in dmACC myo-inositol diverged from control values with ECT suggesting compensation, while hippocampal change suggested normalization.

show abstract

Section: Introductionmentioning

confidence: 99%

Variations in myo-inositol in fronto-limbic regions and clinical response to electroconvulsive therapy in major depression

Njau

Joshi

Leaver

et al. 2016

Journal of Psychiatric Research

View full text Add to dashboard Cite

show abstract

“…In contrast with these studies, Milne et al found no significant decrease in NAA in either the first-episode or multiple-episode groups 22. Low NAA levels imply neurodegenerative changes, and could be related to age, duration of illness, and number of depressive episodes 18,52. In the study by de Diego-Adelino et al it was found that metabolic alterations were more pronounced in patients with recurrent or chronic depression 53.…”

Section: Discussionmentioning

confidence: 89%

“…Proton magnetic resonance spectroscopy ( 1 H-MRS) studies regarding MDD have reported different alterations in brain metabolites, such as in NAA, glutamate, gamma-aminobutyric acid, choline, and myo-inositol, in different brain regions 17. Studies using MRS have shown abnormalities in brain metabolism in the prefrontal cortex and limbic structures in patients with depression 18. So far, MRS studies of the amygdala have shown alterations in choline, myo-inositol, and glutamate in patients with MDD 19.…”

Section: Introductionmentioning

confidence: 99%

No change in N-acetyl aspartate in first episode of moderate depression after antidepressant treatment: 1H magnetic spectroscopy study of left amygdala and left dorsolateral prefrontal cortex

Janović

Kalember

Janović

et al. 2014

NDT

View full text Add to dashboard Cite

BackgroundThe role of brain metabolites as biological correlates of the intensity, symptoms, and course of major depression has not been determined. It has also been inconclusive whether the change in brain metabolites, measured with proton magnetic spectroscopy, could be correlated with the treatment outcome.MethodsProton magnetic spectroscopy was performed in 29 participants with a first episode of moderate depression occurring in the left dorsolateral prefrontal cortex and left amygdala at baseline and after 8 weeks of antidepressant treatment with escitalopram. The Montgomery-Asberg Depression Rating Scale, the Hamilton Rating Scale for Depression, and the Beck Depression Inventory were used to assess the intensity of depression at baseline and at the endpoint of the study. At endpoint, the participants were identified as responders (n=17) or nonresponders (n=12) to the antidepressant therapy.ResultsThere was no significant change in the N-acetyl aspartate/creatine ratio (NAA/Cr) after treatment with antidepressant medication. The baseline and endpoint NAA/Cr ratios were not significantly different between the responder and nonresponder groups. The correlation between NAA/Cr and changes in the scores of clinical scales were not significant in either group.ConclusionThis study could not confirm any significant changes in NAA after antidepressant treatment in the first episode of moderate depression, or in regard to therapy response in the left dorsolateral prefrontal cortex or left amygdala. Further research is necessary to conclude whether NAA alterations in the first episode of depression could possibly be different from chronic or late-onset depression, and whether NAA alterations in stress-induced (reactive) depression are different from endogenous depression. The potential role of NAA as a biomarker of a treatment effect has yet to be established.

show abstract

“…This is in agreement with the previous researches. A higher lactate/creatinine ratio in the left hippocampus of patients with major depressive disorder, but during treatment, a significantly decreased ratio was observed [28]. Mitani et al [29] found a positive correlation between alanine level and HAMD score, the plasma level of alanine may reflect the severity of depression.…”

Section: Glycolysis/gluconeogensismentioning

confidence: 97%

1H NMR-based metabolic profiling of liver in chronic unpredictable mild stress rats with genipin treatment

Chen

Shi

Xiang

et al. 2015

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Hippocampal neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study

Cited by 20 publications

References 65 publications

Variations in myo-inositol in fronto-limbic regions and clinical response to electroconvulsive therapy in major depression

Variations in myo-inositol in fronto-limbic regions and clinical response to electroconvulsive therapy in major depression

No change in N-acetyl aspartate in first episode of moderate depression after antidepressant treatment: 1H magnetic spectroscopy study of left amygdala and left dorsolateral prefrontal cortex

1H NMR-based metabolic profiling of liver in chronic unpredictable mild stress rats with genipin treatment

Contact Info

Product

Resources

About